MBX Biosciences, Inc.

NasdaqGS:MBX Stock Report

Market Cap: US$3.0b

MBX Biosciences Future Growth

Future criteria checks 0/6

MBX Biosciences's earnings are forecast to decline at 1.9% per annum while its annual revenue is expected to grow at 76.3% per year. EPS is expected to grow by 8.1% per annum. Return on equity is forecast to be -63.4% in 3 years.

Key information

-1.9%

Earnings growth rate

8.15%

EPS growth rate

Pharmaceuticals earnings growth18.9%
Revenue growth rate76.3%
Future return on equity-63.44%
Analyst coverage

Good

Last updated15 Sep 2026

Recent future growth updates

Recent updates

Seeking Alpha • Jul 06

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

Summary I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical profile and differentiated dosing convenience. MBXX's Precision Endocrine Peptide platform enables longer-acting, less frequent dosing, addressing key safety and compliance issues in hypoparathyroidism and obesity. Canvuparatide's Phase 2 data show strong efficacy and patient benefit, but Phase 3 must address PK variability and long-term calcium control risks. MBXX's obesity pipeline offers asymmetric upside, while $440M cash extends runway into 2029, mitigating near-term financing risk. Canvuparatide's phase 3 readout comes with risk, similar to recent Eneboparatide failing phase 3 trial (although their ph2 was positive), so we see MBX as a speculative buy. Read the full article on Seeking Alpha
Analysis Article • Jun 17

MBX Biosciences (MBX) Stock Looks Fully Valued After New Phase 2 Data

MBX Biosciences (MBX) has drawn fresh attention after publishing full Phase 2 Avail and one-year open-label data for its lead candidate canvuparatide in chronic hypoparathyroidism, alongside confirming plans for a pivotal Phase 3 trial. See our latest analysis for MBX Biosciences. Against this backdrop, MBX Biosciences stock has seen strong momentum, with a 7 day share price return of 29.36% and a 90 day share price return of 41.01%, while the 1 year total shareholder return is very large at...
Analysis Article • Jun 28

Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 13

We're Not Very Worried About MBX Biosciences' (NASDAQ:MBX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Nov 14

MBX Biosciences: Decent Potential For Lead Indication, But Need More Data

Summary MBX Biosciences, a recent IPO, develops precision peptide therapies for endocrine and metabolic disorders, with lead asset MBX 2109 in phase 2 for Hypoparathyroidism. MBX 2109, a once-weekly PTH replacement therapy, shows promising phase 1 results with stable drug concentration and potential to improve patient compliance over daily treatments. Financially, MBX has a market cap of $784mn and a cash runway of 12-14 quarters, sufficient to reach phase 2 trial data by Q3 2025. Despite promising prospects, I will wait for phase 2 trial data and pricing information before considering a position, while monitoring Yorvipath's market performance. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGS:MBX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202830-261-258-2207
12/31/2027N/A-220-195-1808
12/31/2026N/A-151-139-1308
6/30/2026N/A-104-85-83N/A
3/31/2026N/A-87-80-77N/A
12/31/2025N/A-87-82-80N/A
9/30/2025N/A-80-79-78N/A
6/30/2025N/A-77-72-71N/A
3/31/2025N/A-73-67-67N/A
12/31/2024N/A-62-56-55N/A
9/30/2024N/A-55-51-50N/A
6/30/2024N/A-47-44-43N/A
3/31/2024N/A-39-37-37N/A
12/31/2023N/A-33-32-32N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MBX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MBX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MBX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MBX is forecast to have no revenue next year.

High Growth Revenue: MBX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MBX is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/20 05:56
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MBX Biosciences, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eliana MerleBarclays
"Eliana MerleBarclays
Jonathan WollebenCitizens JMP Securities, LLC